University Hospital of Angers
Angers, France
NCT Number: NCT07452952
The main objective is to assess the effect of increased PEEP on echo-Doppler venous congestion in ARDS patients at two PEEP levels, by grading congestion in each venous flow (suprahepatic, renal, portal) as "absent," "moderate," or "severe," and also calculating the VExUS score.
Trial opening soon.
Get Notified18 year–99 year
All sexes
Observational
Angers, France
All analyzes will be carried out with collection intention. All information required by the protocol is obtained from the clinical file of the Intensive care and Hyperbaric Medicine department of Angers University Hospital. This research is not involving humans on prospective data from care. This research does not require any specific investigation and does not involve no changes to support.
Clinical and biological data to be collected at inclusion (D1) :
Assessments to be carried out as part of routine care on D1, between D3 and D5 and between D6 and D8 :
Then the VExUS score, integrating these three signals as well as the study of the diameter of the inferior vena cavan by ultrasound, is calculated as follows:
End of monitoring data (D28):
During this visit, the following elements will be collected:
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
Non-interventionnal study
Time frame: Baseline
The evolution of venous congestion between two PEEP levels (high and low), assessed by analyzing each Doppler flow individually (hepatic veins, renal interlobar veins, and portal vein) and grading them as 'absent,' 'moderate,' or 'severe,' as well as by the VExUS score, graded from 0 to 3.
Time frame: From Baseline to day 8
Measurement of pulmonary pressures (PAPs, PAPm, PAPd, PAPO) via Swan-Ganz catheters at each PEEP level (high and low)
Time frame: From baseline to Day 8
Time frame: From baseline to Day 8
Time frame: From baseline to day 28
Vexus score greater than or equal to 2 and/or change in portal flow, renal venous flow, or suprahepatic venous flow
Time frame: From baseline to Day 28
Description: score greater than or equal to 2 and/or change in portal flow, renal venous flow, or suprahepatic venous flow
Time frame: from day 3 to day 5
The evolution of venous congestion between two PEEP levels (high and low), assessed by analyzing each Doppler flow individually (hepatic veins, renal interlobar veins, and portal vein) and grading them as 'absent,' 'moderate,' or 'severe,' as well as by the VExUS score, graded from 0 to 3.
Time frame: From Day 6 to Day 8
The evolution of venous congestion between two PEEP levels (high and low), assessed by analyzing each Doppler flow individually (hepatic veins, renal interlobar veins, and portal vein) and grading them as 'absent,' 'moderate,' or 'severe,' as well as by the VExUS score, graded from 0 to 3.
Time frame: From baseline to day 8
Measurement of TAPSE (Tricuspid annular plane systolic excursion), tricuspid S' wave, peak tricuspid regurgitation velocity at each PEEP level (high and low)
Contact information is provided by the study sponsor or research team.
University Hospital, Angers
Other Gov
Acronym: SURVEX
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT05922631
Acute Respiratory Distress Syndrome, Cardiovascular Diseases
Wuhan, Hubei, China
View Trial DetailsNCT06938217
Acute Hypoxemic Respiratory Failure, Acute Respiratory Distress Syndrome (ARDS)
San Antonio, Texas, United States
View Trial DetailsNCT01854424
Acute Respiratory Distress Syndrome (ARDS), Fibrosis
Paris, France
View Trial DetailsNCT05492344
ARDS, Human, Lung Diseases
Brussels, Belgium
View Trial Details